Skip to main content
SpringerLink
Log in

Current Scope of Prostate Cancer

  • Chapter
  • First Online:
Image Guided Prostate Cancer Treatments

  • 1869 Accesses

Abstract

Prostate cancer statistics and ambivalence about screening challenge our profession to enlarge our array of clinical practices in order to better serve patients’ needs. The diagnostic and treatment conventions that dominated urologic practice at the turn of the millennium are rapidly evolving toward an image-guided target-and-manage approach to the disease. Advances in imaging coupled with biomarkers enable more informed decisions about the timing and utilization of diagnostic and treatment interventions. In addition to advanced imaging technologies, complementary and alternative medicine also offer hope for preventing, managing, and overcoming prostate cancer. The overall statistics for prostate cancer challenge our profession to serve patients’ needs by enlarging our array of clinical choices.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 149.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • American Cancer Society. Cancer Facts & Figures 2012. Atlanta, GA: American Cancer Society; 2012.

    Google Scholar 

  • Amling CL, Blute ML, Lerner SE, Bergstralh EJ, Bostwick DG, Zincke H. Influence of prostate-specific antigen testing on the spectrum of patients with prostate cancer undergoing radical prostatectomy at a large referral practice. Mayo Clin Proc. 1998;73(5):401–6.

    Article  PubMed  CAS  Google Scholar 

  • Bard R. DCE-MRI of prostate cancer. Berlin: Springer; 2009. p. 88.

    Google Scholar 

  • Bott SR, Ahmed HU, Hindley RG, Abdul-Rahman A, Freeman A, Emberton M. The index lesion and focal therapy: an analysis of the pathological characteristics of prostate cancer. BJU Int. 2010;106(11):1607–11.

    Article  PubMed  Google Scholar 

  • Carroll P and Shinohara K. Transrectal ultrasound guided biopsy. UCSF Patient Guide 2008 http://urology2008-2012.ucsf.edu/patientGuides/pdf/uroOnc/Prostate_Biopsy.pdf

  • Ewing J. Neoplastic diseases: a textbook on tumors. 4th ed. Philadelphia: Saunders; 1940. p. 844.

    Google Scholar 

  • Hakama M, Auvinen A. Cancer screening. In: Heggenhougen K, Quah SR, editors. International encyclopedia of public health. San Diego: Academic; 2008. p. 464–80.

    Chapter  Google Scholar 

  • Hess D. Evaluating alternative cancer therapies. Edited collection of interviews of leaders of the CAM cancer therapy movement. New Brunswick: Rutgers University Press; 1999.

    Google Scholar 

  • Klotz L. Active surveillance with selective delayed intervention is the way to manage ‘good-risk’ prostate cancer. Nat Clin Pract Urol. 2005;2(3):136–42; quiz 131 p following 149.

    Article  PubMed  Google Scholar 

  • Lepor H. Is targeted minimally invasive therapies (MIAT) ready for prime time? Presented In: Advances in prostate imaging and focal ablative treatment of prostate cancer conference, New York, University Langone Medical Center; 2013.

    Google Scholar 

  • Li J, Djenaba J, et al. Recent trends in prostate cancer incidence by age, cancer stage, and grade, the United States, 2001–2007. Prostate Cancer. 2012. Article ID 691380, 8 pages. doi:10.1155/2012/691380.

  • Martin RM, Gunnell D, Hamdy F, Neal D, Lane A, Donovan J. Continuing controversy over monitoring men with localized prostate cancer: a systematic review of programs in the prostate specific antigen era. J Urol. 2006;176(2):439–49.

    Article  PubMed  Google Scholar 

  • Mearini L, Porena M. Pros and cons of focal therapy for localized prostate cancer. Prostate Cancer. 2011. Article ID 584784, 8 pages. doi:10.1155/2011/584784.

  • Prostate Cancer Foundation. Eliminating cancer as a cause of death by 2015. Panel discussion presented during the 2004 Global Conference; Los Angeles, CA: 2004.

    Google Scholar 

  • Racioppi M, Palermo G, et al. Hot topics in urological health economics: a mini review. Arch Ital Urol Androl. 2012;84(2):47–52.

    PubMed  Google Scholar 

  • Sauvain J, Sauvain E, Rohmer P, et al. Role of Doppler ultrasound in detection of low risk prostate cancers. Diagn Interv Radiol. 2013;94:60.

    Google Scholar 

  • Schröder F, Hugosson J, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360:1320–8.

    Article  PubMed  Google Scholar 

  • Scosyrev E, Messing EM. Reply to prostate-specific antigen screening for prostate cancer and the risk of overt metastatic disease at presentation: analysis of trends over time. Cancer. 2013;119(5):1113–4.

    Article  PubMed  Google Scholar 

  • Stamey TA, Freiha FS, McNeal JE, Redwine EA, Whittemore AS, Schmid HP. Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer. 1993;71(3 Suppl):933–8.

    Article  PubMed  CAS  Google Scholar 

  • Walsh PC. The influence of finasteride on the development of prostate cancer [ed. comment]. J Urol. 2004;171:506–7.

    Article  Google Scholar 

  • Wei JT, Dunn RL, Sandler HM, et al. Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer. J Clin Oncol. 2002;20(2):557–66.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Bard Cancer Center, Biofoundation for Angiogenesis Research and Development, 121 E. 60th St, New York, NY, 10022, USA

    Robert L. Bard MD

Authors
  1. Robert L. Bard MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robert L. Bard MD .

Editor information

Editors and Affiliations

  1. Biofoundation for angiogenesis Research and Development, Bard Cancer Center, New York, New York, USA

    Robert L. Bard

  2. Department of Radiology, Radboud University Medical Centre, HB Nijmegen, The Netherlands

    Jurgen J. Fütterer

  3. Sperling Prostate Center, Carlstadt, New Jersey, USA

    Dan Sperling

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Bard, R.L. (2014). Current Scope of Prostate Cancer. In: Bard, R., Fütterer, J., Sperling, D. (eds) Image Guided Prostate Cancer Treatments. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-40429-0_1

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-40429-0_1

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-40428-3

  • Online ISBN: 978-3-642-40429-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation